FDAnews Drug Daily Bulletin

Pfizer’s Rheumatoid Arthritis Pill: Not A Slam Dunk (Pharmalot Blog)
“For the past couple of years, Wall Street has bet that a forthcoming Pfizer treatment for rheumatoid arthritis called tofacitinib will become a blockbuster and, crucially, help the drugmaker overcome the arrival of generic competition to several of its biggest selling meds,” blogger Ed Silverman writes. Unfortunately, Silverman reports, “a new survey finds that 55 percent of these doctors say the Pfizer pill would not replace a med they are currently prescribing. And 96 percent of the payers say tofacitinib would not replace a drug that is currently offered in their plans.”